AOP Orphan Diseases

Founded in 1996 and headquartered in Vienna, Austria, AOP Health is a private, commercial-stage company specializing in rare diseases and critical care. It operates with an integrated, full-spectrum business model encompassing R&D, regulatory affairs, manufacturing, and commercialization. The company has established a commercial footprint in Europe and is actively expanding its pipeline across therapeutic areas including cardiology & pulmonology, hemato-oncology, and advanced therapies, positioning itself as a significant regional player in the orphan drug space.

Integrated, full-spectrum development and commercialization model for biologics and small molecules, specializing in identifying and developing therapies for rare diseases and critical care from preclinical through post-marketing.

AOP Health competes with other specialized orphan drug companies (e.g., Swedish Orphan Biovitrum) and the rare disease divisions of large pharmaceutical firms. Its key competitive advantages are its deep, integrated European operational footprint, patient-centric commercial model, and expertise in navigating the EU regulatory environment for niche therapies.